---
run_id: halo-evidence-vs-diagnosis-validation-v9-substrate-workflow-01
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: substrate_workflow
run_number: 1
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 103
prompt_source: condition packet (substrate_workflow) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a substrate preamble plus three reviewed source cards, then the frozen Advisor prompt - see run-packet.md
source_packet_sha256: 8c1fbdb9b2af9238d4533dece4ffc185fda2e1f7ecb6008913243d23d9a67c63
condition_packet_sha256: 8c1fbdb9b2af9238d4533dece4ffc185fda2e1f7ecb6008913243d23d9a67c63
output_file: model-outputs/substrate_workflow.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - substrate_workflow (run 01)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `substrate_workflow`, run 1 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 103, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### Rationale
The current evidence for DraftPath’s success is heavily contaminated by "performance-aware attribution" (BK-0048). The executive team’s praise of the product team's "discipline" and "alignment" follows a strong quarter, but the financial wins are entangled with temporary bundle pricing and sales-led roadmap pitches rather than proven product value.

Furthermore, your usage metrics are "broad activity metrics" that may be masking a lack of actual progress (BK-0007). High usage by managers rerunning samples and initial spikes from adjusters do not validate the core strategic assumption: that DraftPath solves a load-bearing problem for the end-user (BK-0001). The most critical uncertainty is whether the tool provides a usable, explainable output for the adjuster—particularly in regulated segments where it is currently being abandoned.

The **Claim File Review** is the only proposal that tests the "load-bearing diagnosis" of whether the tool actually works in the workflow. Unlike the Usage Quality Sprint (which tracks *if* they use it) or the Commercial Cleanroom (which tracks *if* they buy it), the File Review reveals *why* it is being overridden or abandoned. This provides the independent causal evidence needed to decide if you should scale, pivot, or narrow your focus.

### The Strongest Reason Against This Recommendation
The Claim File Review is a qualitative, small-sample exercise that provides "lagging" evidence of utility. It does not offer the immediate, statistically significant financial validation that the Board likely desires twelve days before budget lock. By choosing this over the Commercial Cleanroom, you sacrifice the ability to prove that DraftPath can drive expansion bookings without the "crutch" of bundle pricing.

### Evidence That Would Change My Mind
I would change this recommendation to the **Commercial Cleanroom** if you could provide evidence that the primary risk to next year's budget is not *product utility* (whether it works), but *pricing elasticity* (whether customers will pay for it at full price). If the "load-bearing diagnosis" is already solved and the only remaining uncertainty is the commercial model, then validating the price point becomes more urgent than validating the workflow.
